Dose-de-escalated focal radiotherapy for primary cutaneous T-cell lymphoma: a lesion-based retrospective cohort study
DOI:
https://doi.org/10.2340/1651-226X.2026.45728Keywords:
Cutaneous T-Cell Lymphoma, Mycosis Fungoides, Radiotherapy, Dose Hypofractionation, Local Control, Treatment Outcome, Patient Reported Outcome MeasuresAbstract
Background and purpose: Radiotherapy (RT) is effective for cutaneous T-cell lymphoma (CTCL), but the optimal focal dose remains debated. We evaluated lesion response, local control, toxicity and patient satisfaction after 2 × 4 Gy compared with higher-dose regimens.
Patient/material and methods: This single-centre retrospective study included CTCL patients treated with RT between 1990 and 2019 at a German university hospital. Lesions receiving 2 × 4 Gy (low-dose) were compared with lesions treated with higher doses (median 34 Gy). Endpoints were complete response (CR), overall response (OR), 1- and 5-year local control rate (LCR; Kaplan–Meier/log-rank), in-field relapse and toxicity (common terminology criteria for adverse events/ Radiation Therapy Oncology Group (RTOG)-European Organisation for Research and Treatment of Cancer). Patient satisfaction Freiburg Index of Patient Satisfaction (FIPS) was assessed in a subsample.
Results: Thirty-two patients with 227 lesions were analysed (195 low-dose; 32 higher-dose). CR was achieved in 88.2% vs 90.6% and OR in 94.4% vs 100%, respectively (low- vs higher-dose). LCR was inferior after low-dose RT, with 1- and 5-year LCR estimates of 82 and 67% versus 100 and 96% after higher-dose RT (log-rank p = 0.013). In-field relapse occurred in 20.1% (37/184) vs 3.6% (1/28) of lesions with follow-up (Fisher p = 0.034). No toxicity > grade 2 was observed, and did not differ between groups (p = 0.695 and
p = 0.657). In 11 FIPS questionnaires, satisfaction was high (mean score 1.27; median 1).
Interpretation: Low-dose 2 × 4 Gy yields excellent initial response with minimal toxicity, but inferior local control compared with higher-dose focal RT. Findings support intent-based dosing: 2 × 4 Gy for symptom-driven treatment with re-irradiation as a pragmatic option, and higher-dose RT when durable local control is the primary objective.
Downloads
References
Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Bernreiter S, Cozzio A, et al. S2k-Leitlinie – Kutane Lymphome (ICD10 C82-C86): update 2021. J Dtsch Dermatol Ges. 2022;20(4):537–55. DOI: https://doi.org/10.1111/ddg.14706_g
Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703–14. DOI: https://doi.org/10.1182/blood-2018-11-881268
Erratum in: Blood. 2019;134(13):1112. DOI: https://doi.org/10.1182/blood-2019-130559
Mehta-Shah N, Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, et al. NCCN guidelines insights: primary cutaneous lymphomas, version 2.2020. J Natl Compr Canc Netw. 2020;18(5):522–36. DOI: https://doi.org/10.6004/jnccn.2020.0022
Latzka J, Assaf C, Bagot M, Cozzio A, Dummer R, Guenova E, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – update 2023. Eur J Cancer. 2023;195:113343. DOI: https://doi.org/10.1016/j.ejca.2023.113343
Elsayad K, Guenova E, Assaf C, Nicolay JP, Trautinger F, Stadler R, et al. Radiotherapy in cutaneous lymphomas: recommendations from the EORTC cutaneous lymphoma tumour group. Eur J Cancer. 2024;212:115064. DOI: https://doi.org/10.1016/j.ejca.2024.115064
Neelis KJ, Schimmel EC, Vermeer MH, Senff NJ, Willemze R, Noordijk EM. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys. 2009;74(1):154–8. DOI: https://doi.org/10.1016/j.ijrobp.2008.06.1918
Patel AM, West L, Atluri PS, Yi SF, Rizvi S, Geethakumari PR, et al. Optimizing palliative focal radiation therapy dose in cutaneous T-cell lymphoma: how low can you go? Pract Radiat Oncol. 2023;13(2):e192–9. DOI: https://doi.org/10.1016/j.prro.2022.10.004
Yahalom J, Dabaja BS, Ricardi U, Ng A, Mikhaeel NG, Vogelius IR, et al. ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood. 2020;135(21):1829–32. DOI: https://doi.org/10.1182/blood.2020006028
Miccio JA, Wilson LD, Kann BH, Jairam V, Beckta J, Foss FM, et al. Cutaneous T-cell lymphoma: trends in radiation doses and patterns of care 2004–2015. Anticancer Res. 2019;39(1):253–9. DOI: https://doi.org/10.21873/anticanres.13105
Wang P, Gilbert M, Lim HW, McHargue C, Friedman BJ, Veenstra JJ, et al. Single-fraction radiation therapy for localized cutaneous T-cell lymphoma. Pract Radiat Oncol. 2023;13(4):346–50. DOI: https://doi.org/10.1016/j.prro.2023.03.015
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–48. DOI: https://doi.org/10.1038/s41375-022-01620-2
National Cancer Institute (US). Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Bethesda (MD): National Cancer Institute; 2017.
National Cancer Institute. Common toxicity criteria (CTC) version 2.0 [Internet]. 1999 [cited 2026 Feb 16]. Available from: https://www.eortc.be/services/doc/ctc/
Schoenthaler M, Farin E, Karcz WK, Ardelt P, Wetterauer U, Miernik A. Der Freiburger Index für Patientenzufriedenheit. Vorstellung eines neuen Instruments und seiner psychometrischen Eigenschaften [The Freiburg index of patient satisfaction: introduction and validation of a new questionnaire]. Dtsch Med Wochenschr. 2012;137(9):419–24. German. DOI: https://doi.org/10.1055/s-0031-1298976
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4. DOI: https://doi.org/10.1001/jama.2013.281053
Hoppe RT. Mycosis fungoides: radiation therapy. Dermatol Ther. 2003;16(4):347–54. DOI: https://doi.org/10.1111/j.1396-0296.2003.01647.x
Mazzeo E, Rubino L, Buglione M, Antognoni P, Magrini SM, Bertoni F, et al. The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: principles and indications. Rep Pract Oncol Radiother. 2013;19(2):77–91. DOI: https://doi.org/10.1016/j.rpor.2013.07.009
Kempf W, Mitteldorf C. Cutaneous T-cell lymphomas – an update 2021. Hematol Oncol. 2021;39(Suppl 1):46–51. DOI: https://doi.org/10.1002/hon.2850
Oymanns M, Daum-Marzian M, Bellm A, Elsayad K, Eich HT, Assaf C. Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma. Br J Dermatol. 2023;188(1):145–6. DOI: https://doi.org/10.1093/bjd/ljac012
Rolf D, Elsayad K, Eich HT. Acute and sub-acute toxicity profile of ultra-hypofractionated low-dose total skin electron beam with two 4 Gy fractions for cutaneous T cell lymphoma. J Cancer Res Clin Oncol. 2021;147(6):1757–61. DOI: https://doi.org/10.1007/s00432-020-03449-7
Specht L, Dabaja B, Illidge T, Wilson LD, Hoppe RT, International Lymphoma Radiation Oncology Group. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92(1):32–9. DOI: https://doi.org/10.1016/j.ijrobp.2015.01.008
König L, Hörner-Rieber J, Bernhardt D, Hommertgen A, Rieken S, Debus J, et al. Response rates and recurrence patterns after low-dose radiotherapy with 4 Gy in patients with low-grade lymphomas. Strahlenther Onkol. 2018;194(5):454–61. English. DOI: https://doi.org/10.1007/s00066-018-1277-3
Wong R, Jones G, Farrar N, Sur R, Wilson LD. Local superficial radiotherapy (LSRT) for newly diagnosed stage IA patch-plaque mycosis fungoides (MF) with only one, two or three presenting lesions. Int J Radiat Oncol Biol Phys. 2003;57(2):S289–90. DOI: https://doi.org/10.1016/S0360-3016(03)01145-3
Wilson LD, Kacinski BM, Jones GW. Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (Mycosis Fungoides). Int J Radiat Oncol Biol Phys. 1998;40(1):109–15. DOI: https://doi.org/10.1016/S0360-3016(97)00553-1
Sampogna F, Frontani M, Baliva G, Lombardo GA, Alvetreti G, Di Pietro C, et al. Quality of life and psychological distress in patients with cutaneous lymphoma. Br J Dermatol. 2009;160(4):815–22. DOI: https://doi.org/10.1111/j.1365-2133.2008.08992.x
Fabian A, Rühle A, Liegl G, Domschikowski J, Trommer M, Ferdinandus S, et al. Quality of life in cancer patients at the end of radiotherapy compared to a general population sample in Germany. Int J Cancer. 2026;158(4):1021–30. DOI: https://doi.org/10.1002/ijc.70152
Dabaja B. Renaissance of low-dose radiotherapy concepts for cutaneous lymphomas. Oncol Res Treat. 2017;40(5):255–60. DOI: https://doi.org/10.1159/000470845
Thomas TO, Agrawal P, Guitart J, Rosen ST, Rademaker AW, Querfeld C, et al. Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2013;85(3):747–53. DOI: https://doi.org/10.1016/j.ijrobp.2012.05.034
Winther AH, Vikström S, Brauner H. Transformed mycosis fungoides with penile involvement successfully treated with local radiation. Acta Oncol. 2023;62(4):404–6. DOI: https://doi.org/10.1080/0284186X.2023.2199941
Shikama N. Local radiation for cutaneous T-cell lymphoma other than mycosis fungoides and Sézary syndrome. Chin Clin Oncol. 2019;8(1):8. DOI: https://doi.org/10.21037/cco.2018.07.01
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Philipp Linde, Kathrin Wagner, Johannes Rosenbrock, Michael Oertel, Simone Ferdinandus, Jiaqi Fan, Emmanouil Fokas, Christian Baues
This work is licensed under a Creative Commons Attribution 4.0 International License.
